Longitudinal study based on a safety registry for malaria patients treated with artenimol-piperaquine in six European countries.

Nicolas VignierOlivier BouchaudAndrea AnghebenEmmanuel BottieauGuido CalleriJoaquín Salas-CoronasCharlotte MartinJosé Manuel RamosMatthieu MechainChristophe RappHans-Dieter NothdurftMaria VelascoAzucena BardajíGerardo Rojo-MarcosLeo G VisserChristoph HatzZeno BisoffiTomas JelinekStephan DuparcYann BourhisSilva TommasiniMaurizio IannucelliAntonella BacchieriGiovan Giuseppe MatteraEmilio Merlo PichRonald H Behrens

Published in: Malaria journal (2021)

APQ appears as an effective and well-tolerated drug for treatment of malaria in patients recruited in European countries. AEs and QT prolongation were in the range of those obtained in larger cohorts from endemic countries. Trial registration This study has been registered in EU Post-Authorization Studies Register as EUPAS6942.

Keyphrases

plasmodium falciparum
end stage renal disease
drug induced
ejection fraction
newly diagnosed
chronic kidney disease
clinical trial
prognostic factors
peritoneal dialysis
study protocol
patient reported
replacement therapy
open label